Abstract | Research into treatments for diseases of the CNS has made impressive strides in the past few decades, but therapeutic options are limited for many patients with CNS disorders. Nanotechnology has emerged as an exciting and promising new means of treating neurological disease, with the potential to fundamentally change the way we approach CNS-targeted therapeutics. Molecules can be nanoengineered to cross the blood-brain barrier, target specific cell or signalling systems, respond to endogenous stimuli, or act as vehicles for gene delivery, or as a matrix to promote axon elongation and support cell survival. The wide variety of available nanotechnologies allows the selection of a nanoscale material with the characteristics best suited to the therapeutic challenges posed by an individual CNS disorder. In this Review, we describe recent advances in the development of nanotechnology for the treatment of neurological disorders-in particular, neurodegenerative disease and malignant brain tumours-and for the promotion of neuroregeneration.
Introduction
A number of obstacles present substantial challenges when attempting to treat CNS disorders. For example, systemically delivered products must pass through the blood-brain barrier (BBB), and substances delivered intracranially must withstand the substantial dynamic force of cerebrospinal fluid (CSF) flow in the brain inter stitium. 1 In addition, the complex cellular organization of the brain and spinal cord complicates the targeted treatment of specific cell populations. Nanotechnology presents a potential solution to these problems. The term 'nanotechnology' refers to the engineering of materials on the nanoscale, with functional organization of less than 100 nm in at least one dimension. The scale of nano engineered materials enables the structures to interact with biological substrates at a molecular level, providing these materials with the potential to effect change in bio logical systems in unprecedented ways. As such, nano technologies can be broadly applied in the diagnosis, imaging and treatment of neurological disorders.
Nanoengineered materials are relevant, and indeed advantageous, for the treatment of CNS disease for a number of reasons. First and foremost, the materials can permeate the BBB-a common obstacle for CNS targeted therapies. Nanomaterials can also be engineered to interact with defined cellular subsets or molecules, thereby affording specificity of treatment. Furthermore, inclusion of enzyme cleavage sequences in the nano material enables modification of activity in response to biological stimuli, such as pHsensitive modification or cationtriggered selfassembly. Nanofibres and nano scaffolds can provide structural as well as trophic support for either endogenous or transplanted cells. Importantly, nanoengineered materials are multifaceted; multiple fea tures can be incorporated into the structures to provide simultaneous targeting, bioactivity, gene delivery and imaging capabilities in a single material.
In this Review, we provide an overview of nano technologies that have been investigated in the context of neurological disease, discuss the evidence for effi cacy and toxicity of nanomaterials in specific disorders of the CNS, and highlight the potential for translation of n anotechnology to the clinic.
Examples of nanotechnologies
Many different forms of nanotechnology exist (Figure 1 ), each of which provides unique properties that can be utilized for CNS therapeutics. Nanoparticles are highly stable 3D polymeric encapsulation systems that can be loaded with drugs and functionalized with target ing ligands or antibodies, and can be used as nanocarriers to deliver drugs to the CNS. Nanomicelles and nano liposomes are also used for CNStargeted drug deliv ery; nanomicelles comprise a hydrophilic phospho lipid mono layer (or polymer) with a hydrophobic core, whereas nanoliposomes have a lipid bilayer structure similar to that of a vesicle.
Dendrimers are highly organized structures with repeatedly branched polymers that arise from a central core that can also be loaded with drugs. Aptamers are singlestranded DNA or RNA molecules that are folded into specific 3D structures that can bind to targets with high affinity. Nanofibres are long, linear arrangements of nanomaterials that can selfassemble and provide struc tural support and guidance to neighbouring cells. This form of nanomaterial can be organized into nanogels that serve as 3D scaffolds to organize transplanted cells as well as promote cell adhesion and growth. Nanoscale ma terials can also be engineered from carbon; for example, ful ler enes and their derivatives are spherical assemblies of 60 carbon atoms arranged in the same pattern as a soccer ball. A subset of fullerenes includes carbon nanotubes -hexagonal arrays of carbon that are similar in structure to graphite. This wide variety of available technologies enables the selection of a nanoscale mat erial with the characteristics best suited to the therapeutic challenges posed by an individual CNS disorder, and is one of the main advantages provided by nanotechnology.
Neurodegenerative diseases
Neurodegenerative diseases are among the most debili tating of CNS disorders. Over 6 million Americans are affected by the two most common neurodegenerative diseases-Alzheimer disease (AD) and Parkinson dis ease (PD)-and this number can only rise as the popula tion continues to age. 2, 3 Although advances have been made with regard to understanding the aetiology of these dis eases, currently available treatments for CNS disorders are only able to temporarily alleviate symptoms, and delivery of therapeutics to the brain remains a considera ble challenge. As such, novel approaches to the treatment of AD and PD have become a focus of nanotechnology research (Table 1) .
Alzheimer disease
The pathological hallmarks of AD-the leading cause of dementia worldwide-include plaques of amyloidβ (Aβ) and neurofibrillary tangles of hyperphos phorylated tau. The peptides and aggregates of Aβ are neurotoxic and have been proposed as the inciting insult in AD, 4 although tau aggregates are also neurotoxic and can impair cognition. 5 The pathological features of AD are accompanied by increased oxidative stress, 6 elevated levels of metal ions, 7 and the eventual death of many neuronal subsets such as basal forebrain cholinergic neurons, which are among the earliest neurons affected by AD pathology. 8 
Nanoscale inhibition of Aβ aggregation
Inhibition of Aβ plaque formation is the most extensively investigated nanotechnologybased approach to AD treatment. 9 Conditions that mimic the cell membrane Key points ■ To be effective, therapies for CNS disorders must overcome hurdles including the blood-brain barrier, the complex cellular architecture of the CNS, and the multifactorial nature of CNS disease ■ Nanotechnology-engineering of materials that measure less than 100 nm in at least one dimension-can combat these challenges, and enable multimodal therapeutic targeting at the molecular level ■ The efficacy of nanoscale treatments has been demonstrated in models of neurodegenerative disease, neuroregeneration and brain tumours, but few of these treatments have been successfully translated to the clinic ■ The future of nanotechnology in clinical neuroscience will rely on our ability to interface this technology with our burgeoning understanding of the molecular underpinnings of CNS disease environment are known to promote αhelical confor mations of Aβ, which mitigates the capacity of Aβ to aggregate into plaques. 10 Accordingly, nanomicelles composed of phospholipids (a major component of the cell membrane) stabilized by the addition of poly ethylene glycol (PEG) inhibited βpleated sheet formation and aggregation of Aβ, and attenuated Aβinduced neuro toxicity in the SHSY5Y human neuroblastoma cell line in vitro. 11 The phytochemical curcumin was also found to alleviate Aβ oligomerization and cytotoxicity in vitro, 12 but the compound exhibited poor bioavailability when injected into mice. Incorporation of curcumin into nano liposomes improved its bioavailability while maintaining its capacity to potently inhibit Aβ aggregation. 13, 14 Chelating agents provide another tactic in AD therapeutics, owing to the fact that increased levels of metal ions, such as copper, precipitate the formation of Aβ plaques. 15 For example, the copper-zinc chelator clioquinol reversed Aβ plaque formation and improved cognition in ADlike transgenic mice, 16 and demon strated modest efficacy in a pilot phase II clinical trial in patients with AD. 17 Although clioquinol is hydrophobic and thus able to cross the BBB, the compound has been associated with adverse neurological effects, prompting investigations into alternative chelators for AD therapy. Microemulsion nanoparticles conjugated to the known copper chelator dpenicillamine were found to dissolve preexisting Aβ aggregates in vitro. 18 The combination of microemulsion nanoparticles with dpenicillamine should allow this intrinsically hydrophilic drug to cross the BBB, so this nanocarrier system could be a viable alternative to traditional chelating agents in the tr eatment of AD.
In addition to nanoparticles, selfassembling c holesterolbearing pullulan nanogels have been investi gated in the context of AD owing to their function as artificial molecular chaperones for misfolded pro teins. 19 These nanogels inhibited Aβ aggregation 20 and reduced neurotoxicity of primary cortical neuron cultures in vitro. 21 Although the various nanotechnology methodolo gies described above have not been investigated in vivo, the cellular findings that we have outlined suggest that further translational study of nanoscale inhibitors of Aβ aggregation as potential AD therapeutics is warranted.
Fullerenes as neuroprotectants
Oxidative damage is an early outcome of AD pathol ogy, 22 and has prompted interest in antioxidants as potential treatments for this disorder. On the nanoscale, derivatives of fullerenes are wellcharacterized as potent freeradical scavengers. 23 These compounds are neuro protective against the excitotoxicity induced by gluta mate receptor agonists, including kainic acid, in mouse cortical neuron cultures. 24 The neuroprotective efficacy of fullerene derivatives has been demonstrated in an in vivo proofofprinciple study using a genetic mouse model of amyotrophic lateral sclerosis (ALS). 25 Fullerene mediated neuroprotection against Aβ toxicity in vitro or in genetic mouse models of AD in vivo has not yet been demonstrated. However, the findings that fullerene deriv atives inhibit fibrillization of Aβ peptide, and that intra ventricular administration of hydrated fullerene in rats prevented Aβinduced cognitive impairments, 26 suggest that fullerenes have multiple synergistic mechanisms that could be utilized for the treatment of AD.
Cholinergic nanocarriers
Given the marked cholinergic deficit observed in patients with AD, current treatments approaches, including those based on nanotechnology, aim to enhance cholinergic activity through the use of cholinesterase inhibitors. 27 Acetylcholine has a short halflife and does not readily cross the BBB, so nanocarriers for acetylcholine, such as singlewalled carbon nanotubes that can cross the BBB and are taken up by cells, have been explored. When nanotubes were loaded with acetylcholine and administered systemically in a kainicacidinduced mouse model of AD the acetylcholineloaded particles restored cog nitive function to preAD levels, as assessed on behavioural tests of learning and memory, whereas administration of free acetylcholine did not elicit any effect. 28 As the biocompatibility of carbon nanotubes has been a concern (as discussed below), 29 researchers also sought to investigate the basis of cellular toxicity by the nanomaterial. They identified a cytotoxicityfree dose range that was associated with carbon nanotube delivery specifically to lyso somes (the pharmacological target organelle), and not to mitochondria. 28 Although the timeframe of disease in this study did not reflect the chronic course of AD, the promising results suggest that carbon nanotubes are viable nanocarriers that could be used in the treatment of neurodegenerative disorders.
Nanoparticles have also been used to encapsulate cholinesterase inhibitors, such as rivastigmine, which have been used clinically to treat patients with demen tia. Poly(nbutylcyanoacrylate), also known as PBCA, adsorbs various apolipoproteins from the blood to enable binding of the particle to the LDL receptor on BBB endothelial cells, which facilitates transcytosis of the nanoparticle across the cell layer, thus deliver ing the encapsulated drug into the CNS. 30 BBBcrossing is further enhanced when the PBCA nanoparticles are coated with polysorbate80; compared with uncoated particles, polysorbate80coated PBCA particles signifi cantly increased delivery of rivastigmine to the brains of rats when injected intravenously. 31 Treatment with p olysorbate80coated PBCA particles also improved spatial learning and memory in scopolaminelesioned mice. 32 These results suggest that nanocarriers are an effective means of enhancing the effects of cholinesterase inhibitors for the treatment of AD.
Parkinson disease
Selective loss of dopaminergic neurons in the substan tia nigra pars compacta, and brainstem accumulation of αsynuclein aggregates (Lewy bodies), are the most prominent pathological features of PD-the second most common neurodegenerative disorder worldwide. 33 Given the specific depletion of dopaminergic activity in PD, cur rent treatments largely focus on enhancing levels of dopa mine in the brain. 34, 35 Although these treatments have produced marked improvement of symptoms in patients with PD, they do not alter progression of the underlying disease process. Alternative approaches, including the use of nanotechnology, either alone or in combination with therapies such as gene therapy, tar geted cell transplantation or deep brain stimulation, are currently being explored.
Nanoscale gene delivery
Gene delivery has been extensively evaluated in the context of PD, with efforts aimed at increasing striatal dopamine, inhibiting the subthalamic nucleus, or pro moting survival of nigrostriatal dopaminergic neurons. 36 Traditional gene therapy studies used viral vectors for DNA delivery, but concerns regarding the toxicity and immunogenicity of these materials have been raised. 
REVIEWS
Nanotechnology offers attractive alternatives to virus based systems. 37 Complexing of nanogels of PEG and polyethylenimine with antisense oligonucleotides enabled efficient transport of the material across an in vitro BBB model. 38 When injected intravenously, the nanogels also delivered the oligonucleotides to the brain, and the efficacy of this process was particularly enhanced when the gels were functionalized with insulin or trans ferrin molecules. Analogous to the pharmacological inhibition of dopamine degradation that is already in use clinically, this gene delivery system could be combined with antisense oligonucleotides that block monoamine oxidase B function to augment dopaminergic activity in patients with PD.
The capability of transferrin to facilitate BBB cross ing via receptormediated transcytosis has also been exploited using nanoliposomebased gene therapy. A single intravenous administration of PEGylated lipo somes encapsulating tyrosine hydroxylase encoding plasmids conjugated to a transferrin receptor anti body successfully restored striatal tyrosine hydroxylase enzyme activity and reversed motor impairment in a 6hydroxydopamine (6OHDA) model of PD in rats. 39 Single molecules of DNA can be compacted into nano particles using polycations, such as lysine oligo mers, for direct delivery to the brain. Injection of DNA nano particles encoding glial cell linederived neuro trophic factor (GDNF)-an established neurotrophic factor for mesencephalic dopamine neurons-into rat striatum lesioned with 6OHDA strikingly increased the survival of subsequently grafted embryonic dopa minergic neurons. 40 Importantly, pretreatment with GDNFDNA nanoparticles also enhanced the behav ioural improvement observed with engrafted tyrosine hydroxylase positive neurons alone, suggesting that this method of gene delivery may be particularly effective when combin ed with therapeutic cell transplantation.
Fullerenes as neuroprotectants
As oxidative damage is also likely to be involved in the pathogenesis of PD, 41 the neuroprotective effects of fullerenes have been explored in the context of this dis ease. Fullerene treatment resulted in potent neuro protec tion of mesencephalic dopaminergic neuron cultures that had been treated with either 6OHDA or 1methyl 4phenylpyridinium (MPP+), a metabolite of 1methyl 4phenyl1,2,3,6tetrahydropyridine. 42 Further more, in both the 6OHDA and MPP+ models, fullerene treat ment proved more effective than GDNF. Fullerenes have also been studied in an in vivo intra nigral ironinfusion model of PD. Concomitant infusion of antioxidant carboxy fullerene prevented the degeneration of tyrosine hydroxylasepositive striatal neurons. 43 The above find ings suggest that fullerenes may improve the symptoms of PD, consistent with the demonstrated efficacy of this nanotechnology in models of AD and ALS.
Carbon nanotubes
Multiwalled carbon nanotubes loaded with nerve growth factor (NGF) have been shown to promote neurite out growth in both dorsal root ganglion neurons and PC12 cells in vitro. 44 Another study found that the conduc tive properties of carbon nanotubes supported electri cal activity of neurons. 45 The findings from these two studies suggest that carbon nanotubes could enhance integration of cells transplanted into the striatum, par ticularly if the nanotubes are loaded with GDNF. Electrical stimulation of carbon nanotubes was found to directly stimulate neuronal activity, 46 which raises the intriguing possibility of a carbonnanotubebased deep brain stimulation method for the treatment of PD.
The translation of carbon nanotube technology to the treatment of human neurological disorders is not with out obstacles, with biocompatibility of these ma terials as the primary concern. 47 Carbon nanotubes were found Abbreviations: 6-OHDA, 6-hydroxydopamine; GDNF, glial cell line-derived neurotrophic factor; PBCA, Poly-n-butylcyanoacrylate; PEG, polyethylene glycol; PLGA, poly(lactic-coglycolic-acid).
to induce both apoptosis and necrosis in a variety of cell lines. 48 Notably, singlewalled nanotubes demonstrated more in vitro cytotoxicity than their multiwalled counter parts. No cytotoxicity was observed when cells cultured under identical conditions were treated with fuller ene, indicating that the nanoarchitecture of the carbon n anotubes is the factor that causes the adverse effects.
Carbon nanotubes also increased oxidative stress in keratinocytes; 49 given the importance of antioxidant neuro protection outlined above, the cytotoxic response to this nanotechnology is particularly disappointing with regard to its potential application in neurodegenerative disease. Recent research that utilized improved purifica tion methods in carbon nanotube synthesis and carbon nanotubes with additional side groups has achieved much lower levels of toxicity, 50, 51 suggesting that the rela tive biological incompatibility of carbon nanotubes could be overcome after sufficient optimization.
Neuroregeneration
Regeneration in the CNS constitutes a persistent clini cal obstacle. As damaged or transected axons in the mammalian brain or spinal cord are generally unable to repair themselves, permanent neurological deficits com monly occur. Barriers that prevent regeneration of the CNS include the presence of extrinsic inhibitory mol ecules, intrinsic declines in regenerative capacity with age, the need to repair a heterogeneous population of cells, and the fact that repair requires careful guidance during axon regeneration for the successful rewiring of the intricate neuronal network. 52, 53 Current research is focused primarily on inhibition of glial scar formation after injury, promoting remyelination of axons that are attempting regeneration, and transplantation of stem cells to foster a permissive environment for CNS repair (Table 2) . 54 Nanotechnology is particularly wellsuited for such multimodal therapy; for example, bio degradable porous polyllactic acid nanoscaffolds can support neu rite outgrowth from cultured neural stem cells, 55 and when these scaffolds are assembled by electro spinning to create aligned channels they can direct neurite out growth parallel to the nanoscaffold longitudinal axis. 56 These principles of generic neural tissue engineering have been applied in the areas of optic nerve re generation and spinal cord injury (SCI).
Optic nerve regeneration
Restoration of the retinal ganglion cell axons that com prise the optic nerve is relevant not only to the treat ment of traumatic injury, but also for the treatment of numerous optic neuropathies such as optic neuritis, mitochondrial disorders (Leber hereditary optic neuro pathy) and glaucoma. 57 Current approaches to these dis orders include immunomodulation via the targeting of resident macrophages, delivery of neurotrophic factors to the injury site, and inhibition of glial scar components. Notably, combined approaches that enable simultaneous targeting of numerous pathways yield the most favour able results. 58 The scope for combining therapies is one of the main advantages of nanotechnology.
Nanofibre scaffolds
Selfassembling peptide nanofibre scaffolds have been utilized to enhance optic nerve regeneration. In the pres ence of physiological salt concentrations, these nanofibre scaffolds form spontaneously from individual peptides and, as they consist solely of lamino acids, are entirely biocompatible. 59 One such nanofibre scaffold, composed of Arg-Ala-Asp-Ala (RADA) peptides, can support neurite outgrowth by PC12 cells as well as synapse for mation by hippocampal neurons in vitro. 60 Furthermore, in a hamster model of optic tract tran section, the RADA based scaffold was able to support axon regeneration through the lesion site, which was accompanied by partial restoration of visual function. 61 Although impressive, these findings are difficult to relate to the clinical setting, as the selfassembling pep tide solution was applied at the time of injury, which would not be realistic in human patients. To address this issue, the same group established a model of chronic optic tract injury. The researchers also used Mn 2+ enhanced MRI (MEMRI) as a noninvasive means to follow optic tract regeneration in real time. In this system, the nanofibre scaffold was applied 105 days after optic tract transection, with MEMRI and behavioural assessments being performed in the 45 days following treatment. Sparse regeneration of optic tract fibres was visible in scaffoldtreated animals on both MEMRI and histological imaging, 62 suggesting that the optic nerve maintains regenerative potential long after injury occurs. Notably, no functional recovery was observed follow ing the nanoscaffold treatment. The authors suggest that this outcome might be explained by insufficient numbers of spared ganglion cell axons in the transec tion model, or by neuronal toxicity of the Mn 2+ that was used as a contrast agent. Nevertheless, optimization of this nanofibre technology, perhaps in combination with other techniques that aim to provide a biological signal to regenerat ing axons, holds great promise for promoting CNS repair after injury.
Nanoscale drug delivery
Nanotechnology has also been used to enhance delivery of trophic factors and glial scar inhibitors to promote optic nerve repair. PEG hydrogels encapsulating ciliary neurotrophic factor (CNTF)-a molecule known to promote survival and axon regeneration of retinal gan glion cells 63 -provide a method for the controlled release of CNTF over weeks to months, with release kinetics that can be modified by the density of the hydrogel. 64 In cul tured retinal explants, CNTFloaded hydrogels promoted neurite outgrowth that was indistinguishable from the outgrowth produced by media supplementation with CNTF alone. 64 Although the treatment was not tested in an animal model, it seems likely that the slow, controlled release of CNTF provided by the PEG hydrogel would have a prolonged neuroregenerative effect in vivo.
Epidermal growth factor receptor (EGFR) inhibitors have also been investigated in neuroregeneration, as acti vation of this receptor following CNS injury promotes the deposition of growthinhibitory molecules such as chondroitin sulphate proteoglycans. 65, 66 Indeed, local application of smallmolecule EGFR kinase inhibitors promoted in vivo axon regeneration in an optic nerve crush injury model. 67 However, the treatment required daily application of the EGFR inhibitor directly to the injured optic nerve, which would not be feasible in a clinical setting. To achieve similar local delivery in a minimally invasive manner, nanospheres composed of poly(lacticcoglycolic acid)-also known as PLGA -were loaded with the EGFR kinase inhibitor AG1478 and delivered via the eye to rats after an optic nerve crush injury. 68 AG1478containing nanospheres poten tiated axon regeneration beyond the site of injury at 4 weeks. Importantly, this result was not achieved when the AG1478 was encapsulated in PLGA microspheres, suggesting that nanoscale encapsulation of the drug directly contributed to its efficacy, perhaps owing to the constant rate of release of the drug from nanospheres, as opposed to an initial burst then decreased release as observed with microspheres. 68 Spinal cord injury Injuries to the spinal cord affect millions of people world wide, costing the US healthcare system alone over 40 billion dollars annually. 69, 70 Consequently, strategies to promote functional repair of the spinal cord after injury have been a major focus of translational neuro science research. Techniques that encourage regrowth of severed nerve tracts, inhibit glial scar formation, enhance remyelina tion and augment plasticity of spared fibres have all shown some efficacy in animal models. 71 In recent years, stem cellbased approaches have received much attention. 72 Some of these methods have been trans lated to clinical trials and have shown good safety profiles, but few, if any, have demonstrated efficacy with regard to patient recovery. 73 Nanotechnology seems likely to provide tools that are superior to our current inadequate arsenal of therapies for SCI.
Hydrogels
Owing to the porous hydrophilic nature, polymer hydro gels are particularly well suited to neuro regenerative appli cations. Implantation of hydrogels composed of poly(N[2hydroxypropyl] methacrylamide)-a bbreviated to PHPMA-into spinal cord tran section cavities can bridge the tissue defect and competently sup port angiogenesis and axonal ingrowth. 74 Func tional ization of the hydrogel with an Arg-Gly-Asp (RGD) peptide facilitates cell adhesion via fibronectin receptors 75 and enables infiltration of the gel into sur rounding cells, thus creating a beneficial environment for spinal cord repair. Indeed, in a rat model of SCI, implantation of PHPMA-RGD hydrogels led to axon regeneration through the lesion site (as observed using anterograde axonal labelling) and recovery of some hindlimb motor function. 76 Although these findings are encouraging, the implantation of a preassembled hydro gel scaffold to fill the defect requires invasive surgery. To minimize this requirement, hydrogels that assem ble in situ when exposed to light have been developed. Degradable poly(lactic acid)-PEG (PLA-PEG) hydrogels loaded with neurotrophin3 (NT3)-a molecule that has been extensively studied in the context of spinal cord repair 77 -have demonstrated efficacy in in vivo transec tion models of SCI. Treatment with NT3loaded PLA-PEG hydrogels led to controlled neurotrophin release at the site of injury that resulted in reinnervation of both the corticospinal tract and the raphe spinal tract, as well as functional recovery. 78 Nanotechnology provides a method to combine porous scaffolds and growth promoting factors and so holds great potential to aid recovery in patients with SCI.
Nanoscaffolds for stem cell delivery
Stem cells have been subjected to intensive investiga tion as potential therapeutics for SCI. To augment the potential efficacy of such treatments, nanoscale scaf folds aimed at nurturing transplanted stem cells have been explored. Multilayer PLGA scaffolds designed with a porous inner layer for neural stem cell (NSC) seeding and an outer layer of aligned channels to facilitate axon guidance and regrowth have yielded promising results in SCI. 79 Implantation of NSCseeded PLGA scaffolds led to durable functional recovery in animals with a spinal cord transection, including substantial improvement in locomotion, as measured on the Basso, Beattie and Bresnahan scale, that was maintained at 1 year follow ing injury. These improvements seemed to be mediated by enhanced axon regeneration as well as reduction of the glial scar. 79 Nanoscaffolds with longitudinal organization to assist axon regeneration have been examined. A nanofibre scaf fold of crosslinked dextran sulphate and gelatin seeded with human embryonic spinal cord cells promoted func tional recovery in a rat transection model of SCI, with visible evidence of reinnervation in the scaffold. 80 Self assembling nanofibre scaffolds have also been investi gated in the context of SCI. The same RGDcontaining nanofibre scaffold described for optic nerve regenera tion were seeded with neural cells and implanted into transected spinal cords. 81 NSCseeded scaffolds displayed increased axonal innervation compared with nonseeded scaffolds, although animals transplanted with Schwann cellseeded scaffolds showed even greater innervation than animals given NSCseeded scaffolds. The behav ioural outcome of scaffoldinduced neuronal regenera tion was not explored. Notably, as pre assembled scaf folds were used in this study, the utility of the selfassembling nature of this nanomaterial was not investigated.
Self-assembling bioactive peptide amphiphiles
Peptide amphiphile molecules consist of a hydrophobic aliphatic tail region, a linker region of amino acids that form βpleated sheets, and a hydrophilic head group that can be functionalized with a bioactive peptide sequence of choice. 82 In the presence of physiological cation concentrations, peptide amphiphile molecules undergo hydrophobic collapse and selfassemble into nano fibres. This material can, therefore, be injected into neural tissues as a liquid and will then selfassemble into nano fibres in the extracellular spaces. These nano fibres display the peptide head group on the surface at an extremely high density and, when in an aqueous solu tion, further organize into a 3D gel that is capable of acting as a surrogate extracellular matrix. 83, 84 A peptide amphiphile displaying the lamininderived epitope IKVAV 85, 86 was found to potently promote the differentiation of NSCs into neurons while inhibit ing their differentiation into astrocytes in vitro. 87 In the context of SCI, injection of the IKVAVcontaining pep tide amphiphiles around the site of injury led to a dramatic recovery of motor function. 88 Histologically, mice treated with the amphiphiles had few glial scars and showed evidence of regeneration of both ascending and descending nerve fibres. In addition, the remaining serotonergic fibres in mice that received the amphiphile injection showed enhanced plasticity compared with the fibres in shaminjected mice. 89 The positive effects of this amphiphile treatment are entirely dependent on the bioactivity of the IKVAV epitope; studies that used nonbioactive peptide amphiphiles did not recapitulate the findings. Importantly, the above studies were per formed in a contusion model of SCI that is much more akin to human injuries than the traditional transection model, implying that peptide amphiphiles could readily translate to clinical studies.
Brain tumours
Primary brain and CNS tumours constitute a substantial and formidable clinical entity, with over 22,000 new cases and 13,000 brain tumourassociated deaths estimated in the USA in 2011 alone. 90 Patients diagnosed with the most common and aggressive form of these tumours, termed glioblastoma multiforme (GBM), have a median survival of less than 2 years. 91 This bleak prognosis has remained relatively constant for decades, despite con tinued advances in surgical practices, the advent of new radiotherapy techniques, 92 and the undertaking of clinical trials to optimize chemotherapy protocols. 91, 93, 94 Consequently, treatment modalities for GBM remain palliative at best. The need for systemically delivered drugs to pass across the BBB has restricted chemo therapeutic options. In addition, attempts at GBM tailored therapy using specific molecular candidates have yielded disappointing results in clinical trials. 95 Thus, there is considerable room for improvement with respect to the ease of drug administration and molecular targeting to minimize side effects and optimize efficacy of therapies for brain tumours.
Drug delivery

Generic nanocarriers
As access to the brain is a considerable impediment to the application of standard chemotherapeutics for CNS neoplasms, nanocarriers that usher systemic drugs across the BBB have been extensively investigated. Examples of such nanocarriers include PBCA nanoparticles, which have been used to optimize the delivery of metho trexate 96 and temozolomide 97 to the brain, resulting in significantly increased intracerebral drug concentrations compared with treatment with the drugs alone.
Solid lipid nanoparticles (SLNs) have also been applied for delivery of chemotherapeutic agents, such as temo zolomide, 98 etoposide 99 and paclitaxel, 100 to the brain. The SLN formulation of etoposide inhibited prolifera tion of glioma cell lines more effectively than etoposide alone, with a concomitant decrease in cytotoxicity in normal astrocytes, 99 thereby yielding a wider therapeu tic window. Similarly, treatment with SLNentrapped paclitaxel inhibited glioma cell growth in vitro by several orders of magnitude more than did the nonentrapped therapy. 100 This finding translated in vivo to a significant reduction of tumour mass when animals were given the PCBAmediated delivery of paclitaxel compared with standard drug administration. Interestingly, in the paclitaxel SLN study, inhibition of multidrug resistance pumps was observed in the cancerous cells following treatment with the solid lipid nanoparticle formulation. This finding has important implications for the reten tion of chemotherapeutics in specialized glioma cells that become drugresistant owing to the development of drug efflux capabilities. 101 Dendrimers have also been used to deliver anti neoplastic treatments to the brain. Conjugation to polyether-copolyester (PEPE) dendrimers enhanced pas sage of dglucosamine across an in vitro BBB model via gluta mine transporter type 1, and increased the cyto toxicity of methotrexate against U87 and U343 cancer cell lines in culture. 102 Notably, dendrimer encapsula tion of methotrexate was able to overcome acquired resistance to the drug, suggesting that this mode of nanoscale delivery may be able to combat treatment resistance in gliomas. PEGylated polyamidoamine den drimers loaded with doxorubicin also demonstrated an expanded therapeutic window by inhibiting C6 glioma spheroid proliferation while exhibiting little cytotoxicity against brain microvascular endothelial cells in vitro. 103 In summary, generic nanocarriers show great promise for enhanced delivery of chemotherapeutics across the BBB, with curtailed effects on nonneoplastic cells.
Targeted nanocarriers
Nanocarriers can also be functionalized with mol ecules to enable moreprecise targeting to the BBB and efficient drug transport into the brain (Table 3) . PEG-PLGA nanoparticles incorporating a DNA aptamer to target nucleolin, a molecule that is highly expressed in the plasma membrane of both cancer cells and tumour endothelium, 104, 105 enhanced the antiproliferative effects of paclitaxel against C6 glioma cells in vitro. 106 These aptamer nanoparticles strikingly reduced C6 glioma xenograft volumes in nude mice, and prolonged sur vival of animals with C6 intracranial gliomas compared with treatment with either paclitaxel alone or paclitaxel loaded into undecorated nanoparticles. Importantly, the aptamerdecorated nanoparticles showed greater efficacy than undecorated particles, 106 highlighting the value of targeted delivery.
A similar dualtargeting approach has taken advantage of LDL receptorrelated protein (LRP), a molecule that is expressed by the BBB as well as glioma cells. Compared with a nontargeted nanoparticle approach, conjuga tion of PEGcopoly(εcaprolactone) nano particles to a ngiopep-a ligand of LRP that mediates transcytosis across the BBB 107 -enhanced the inhibitory effects of paclitaxel against glioma cells in vitro. 108 These angio pepconjugated nanoparticles enabled increased accu mulation of paclitaxel in intracranial U87 x enografts, but no in vivo efficacy data were presented.
Many GBM tumours exhibit amplification of the EGFR gene, and nanocarriers engineered to exploit this fact have been explored in the context of brain tumours. Immunoliposomes that targeted EGFR (via conju gation of a fragment of cetuximab to the liposome) Abbreviations: EGFR, epidermal growth factor receptor; LRP, LDL receptor-related protein; PCL, polycaprolactone; PEG, polyethylene glycol; PLGA, poly(lactic-coglycolic-acid); PMLA, poly(β-l-malic acid); TRAIL, tumour necrosis factor-related apoptosis-inducing ligand.
significantly enhanced the cytotoxic effects of multiple different chemotherapeutics both in vitro 109 and in mice with U87 xenografts, as well as in xenografts of U87 cells containing a constitutively active deletion mutant form of EGFR known as EGFRvIII. 110 The multimodal capac ity of nanotechnology has also been harnessed using EGFRvIIItargeted iron oxide nanoparticles (IONPs). Conjugation of IONPs to an EGFRvIII antibody pro vided a therapy that augmented apoptosis when admini stered to cultures of either U87 glioma cells (either with or without expression of EGFRvIII) or glioma stem cell neurospheres. 111 For mice with xenografts of EGFRvIII expressing U87 cells, convectionenhanced delivery of the EGFRvIIItargeted IONPs prolonged survival while simultaneously enhancing the visibility of tumours on T2weighted MRI.
Targeted therapy
The studies described above focused on optimizing the packaging and delivery of drugs for the treatment of CNS neoplasms. However, nanotechnology has also been used to develop moretailored therapies (Table 3 ). For instance, cationic albuminconjugated PEGylated (CBSA) nano particles can serve as a nonviral vector for gene delivery of tumour necrosis factor-related a poptosisinducing ligand (TRAIL) plasmid to glioma cells. 112 Administra tion of CBSA-TRAIL nanoparticles enhanced apop tosis of intracranial C6 xenografts, and extended survival of the animals compared with treatment using nonCBSA nano particles. PEG immuno liposomes can also function as nonviral gene delivery systems.
Immunoliposomes loaded with antibodies against the human insulin receptor and antisense mRNA that targeted EGFR transcripts demonstrated cyto toxicity against U87 glioma cells in vitro. 113 When coupled with a transferrin receptor antibody to enable endo thelial transcytosis of the particle across the BBB, these immuno liposomes substantially improved survival of mice bearing intracranial U87 xenografts. 114 Laminin 411, an extracellular matrix protein that is overexpressed by glioma cells and surrounding associated vasculature, has also been used as a target for nanoscale delivery of antisense mRNA. A poly(βlmalic acid) nanoconjugate designed to release laminin411 antisense mRNAs via a pHdependent endosomal escape mechanism induced glioma cell apoptosis in vitro and suppressed xenograft growth and vascularization in vivo. 115 The multimodal aptitude of nanotechnologies has been emphasized in an exciting new study of targeted therapy in a lentivirusmediated genetic mouse model of GBM. Treatment with a nanosystem that combined tumour vascu lature targeting (via addition of a CGKRK peptide), proapoptotic activity using a d(KLAKLAK) 2 peptide, and IONP 'nanoworms' to enhance tumour detection on MRI, caused a substantial reduction in tumori genicity.
116 90% of mice treated with the nano system survived for almost 1 year, whereas untreated animals or mice treated with a nanosystem that lacked the CGKRK targeting peptide all succumbed to dis ease within 3 months. The striking antineoplastic effect of this nanotreatment holds great promise for the develop ment of novel GBM therapeutics that can improve patient survival.
Obstacles to clinical translation
Despite the abundance of data that suggests an unparal leled potential of nanomaterials to aid the treatment of neurological disease, this potential has not yet been realized. To date, only one phase I clinical trial involv ing nanotechnology in CNS therapeutics has been initi ated; this trial, to investigate the use of nanoliposomal irinotecan for the treatment of recurrent glioma, is still recruiting patients. 117 Notably, the trial began 5 years after publication of persuasive evidence on the in vivo efficacy of this nanomaterial, 118 highlighting one of the main reasons why nanotechnology has failed to move into the clinical arena: insufficient evidence from physio logical in vivo studies. Many promising in vitro results are not followed by in vivo correlations. Whether this lack of correlation is a consequence of unfamiliarity regarding the in vivo milieu on the part of many materials scien tists (thus necessitating collaborations with biologists), or whether it is due to the inability of many researchers to replicate in vitro studies in the in vivo setting, is unclear.
Lack of standardization of nanomaterials presents another barrier to the undertaking of nanotechnology based clinical trials. Many different physical and chemi cal properties of nanomaterials, such as size, charge and sur face modifications, affect both their efficacy and toxic ity. 119 For instance, hydrophobic nanomaterials are quickly cleared by the reticuloendothelial system and so primarily accumulate in the liver and spleen before being eliminated. Surface modifications often render nanoparticles more hydrophilic, thereby allowing the particles to remain in the circulation for longer periods of time. 120 In addition, nanomaterial size potently affects clearance: particles of 10-20 nm are efficiently excreted by the kidneys, but renal clearance is not possible for larger nanomaterials. 121 These myriad properties present a challenge both to scientists when attempting to fully characterize nanoengineered materials and render them reproducible, and to regulatory agencies that must con tinually adapt current drug guidelines to facilitate the use of nanotechnologybased therapeutics. 122 Toxicity of nanomaterials is of paramount concern, as underscored by the discussion of carbon nanotubes above. However, most studies of nanoscale therapeutics have failed to address the potential associated toxici ties. The few dedicated studies of nanotoxicity highlight oxidative stress induction, genotoxicity, and immune modulation as three key areas of potential injury by nano engineered therapies. 123 Internalized nanoparticles cause mitochondrial damage, which leads to generation of reac tive oxygen species, activation of proinflammatory sig nalling pathways and, ultimately, cell death. 124 Oxidative stress is also implicated in the DNA damage associated with nanomaterials, raising concerns of tumorigenicity and infertility. 125 Finally, nanoscale therapeutics interact with the immune system on multiple levels. The particles are ingested by macrophages and can induce complement activation and inflammatory reactions. 126 This outcome is particularly important with regard to the use of nano particles in the treatment of malignant brain tumours, as the majority of in vivo preclinical studies in this field have utilized immunocompromised mice, which do not allow investigation of potential immunogenic properties of the nanotechnology.
Conclusions and future directions
The treatment of CNS disorders is stymied by a number of factors, such as the BBB, the complexity of the cellular environment, and the involvement of multiple signalling modalities in any given disease process. Nanotechnology is uniquely poised to address these issues. In models of neurodegenerative disorders, nanoscale approaches have been used to inhibit Aβ oligomerization, reduce reac tive oxygen species, and enhance functional neuronal networks through use of carbon nanotubes. With regard to neuroregeneration, nanoscale scaffolds have success fully guided the appropriate rewiring of the optic nerve and spinal cord, with associated functional recovery in animal models. Nanocarriers have enabled targeted delivery of chemotherapeutics as well as antisense gene therapy, resulting in impressive inhibition of disease pro gression in both in vitro and in vivo models of malignant brain tumours.
Unfortunately, few-if any-of these promising pre clinical studies have been successfully translated to the clinic to influence patient care. Barriers to this success ful translation include insufficient studies of nano material toxicity, immunological compatibility, and a relative paucity of in vivo studies. Moving forward, nano materials could be used as a surrogate niche for transplanted stem cells, providing not only structural support but also sus tained release of signalling factors. In addition, the nano materials themselves can be functionalized to interact with stem cells, both by incorporating bioactive signals and by modifying the mechanical properties of the nano material. Interdisciplinary collaboration will be critical to the success ful clinical translation of nanotechnology.
Although nanotechnology has tremendous potential to affect treatment options in clinical neuroscience, it is unlikely that use of nanotechnology alone will accomplish the complicated task of repairing the CNS. The most efficacious applications of nanomaterials in the treat ment of CNS disease have combined the power of nanoscale interventions with growth factors or cells that enhance the overall effect of the nanoscale treatment, highlighting the importance of a combined approach to nanotherapeutics. Furthermore, the utility of nanotechnology applications in CNS disease can only be augmented by advances in our biological understand ing of the processes involved in these disorders. The synergy between new understanding of the molecular basis of neurological diseases and the multifunctional capabilities of nanotechnology is the factor that stands to fundamental ly change the practice of neurology.
Review criteria
We searched PubMed for articles published up to 4 th March 2012, including electronic early release publications, using terms including "nanotechnology", "nanoparticles", "neuroscience", "central nervous system", and "neurology". Searches for "neurodegenerative diseases", "optic nerve or spinal cord regeneration", "brain tumours", and "toxicity" were also performed. Full-text versions of review and primary research articles were obtained, and references were checked for additional materials when appropriate. The ClinicalTrials.gov database was searched for registered trials of nanotechnology as therapeutics for neurological disorders, using the terms "nanotechnology", "nanoparticles", and "nanoliposomes". Trial descriptions were read to determine whether patients with CNS disorders were included.
